EGFR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9925	1.00	20/20
SCHEMBL10883	1.00	20/20
SCHEMBL11113	1.00	20/20
SCHEMBL33143	1.00	20/20
SCHEMBL9445	0.91	20/20
SCHEMBL26269	0.88	20/20
SCHEMBL8623	1.00	19/20
SCHEMBL8949	1.00	19/20
SCHEMBL11156	1.00	19/20
SCHEMBL11727	1.00	19/20
SCHEMBL24610	1.00	19/20
SCHEMBL24808	1.00	19/20
SCHEMBL25098	1.00	19/20
SCHEMBL25359	1.00	19/20
Dacomitinib Anhydrous (SCHEMBL25637)	1.00	19/20
SCHEMBL25802	1.00	19/20
SCHEMBL33136	1.00	19/20
SCHEMBL33140	1.00	19/20
Dacomitinib Anhydrous (SCHEMBL33147)	1.00	19/20
SCHEMBL33158	1.00	19/20

Clinical trials — most relevant to EGFR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）	PHASE2	RECRUITING
Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules	PHASE2	UNKNOWN
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.	PHASE2	COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC	PHASE1/PHASE2	RECRUITING
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib	PHASE2	COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies	PHASE1/PHASE2	COMPLETED
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors	PHASE1/PHASE2	RECRUITING
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance	PHASE2	COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers	PHASE1	COMPLETED
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations	PHASE1	COMPLETED
TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.	EARLY_PHASE1	RECRUITING
Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.	nan	COMPLETED
The Role of Gene Changes in Brain Tumor Formation and Growth	nan	COMPLETED
Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFR	nan	RECRUITING
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer	nan	RECRUITING
Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy	nan	NOT_YET_RECRUITING
Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors	nan	COMPLETED
A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure	nan	UNKNOWN
PDX Models From EGFR Mutant Tumors	nan	WITHDRAWN
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients	nan	UNKNOWN
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a EGFR binder may also engage these)

Protein	Name	Similarity
P55245	—	0.997	P55245 →
Q01279	—	0.997	Q01279 →
ERBB2	Receptor tyrosine-protein kinase erbB-2	0.978	landscape →
P06494	—	0.973	P06494 →
P70424	—	0.973	P70424 →
Q5RB22	—	0.971	Q5RB22 →
ERBB3	Receptor tyrosine-protein kinase erbB-3	0.971	landscape →
Q60553	—	0.971	Q60553 →
O18735	—	0.965	O18735 →
Q61526	—	0.960	Q61526 →
Q62799	—	0.958	Q62799 →
P11273	—	0.953	P11273 →
NTRK2	BDNF/NT-3 growth factors receptor	0.951	landscape →
Q63604	—	0.951	Q63604 →
Q7TT15	—	0.950	Q7TT15 →
P13388	—	0.950	P13388 →
O70309	—	0.949	O70309 →
Q03351	—	0.949	Q03351 →
P02469	—	0.948	P02469 →
Q9HCM2	—	0.948	Q9HCM2 →
P15209	—	0.948	P15209 →
P39038	—	0.947	P39038 →
Q6IS24	—	0.947	Q6IS24 →
P07942	—	0.946	P07942 →
NTRK3	NT-3 growth factor receptor	0.946	landscape →
Q9P0K1	—	0.946	Q9P0K1 →
Q5IS37	—	0.945	Q5IS37 →
Q91987	—	0.945	Q91987 →
P18614	—	0.945	P18614 →
Q91009	—	0.944	Q91009 →